<DOC>
	<DOCNO>NCT02618850</DOCNO>
	<brief_summary>The purpose study test whether early metabolic response , measure PET/CT scan first cycle chemotherapy , able predict patient advance CRC good prognosis .</brief_summary>
	<brief_title>PET/CT Scan Tool Rationalize Treatment Patients With Advanced ColoRectal Cancer Undergoing First-line Medical Treatment</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Diagnosis histologically confirm colorectal carcinoma stage IV disease patient eligible standard firstline treatment medical therapy ( chemotherapy , indicate association EGFR inhibitor and/or antiangiogenic ) advance disease , diagnosis primary surgery . At least one target nontarget lesion accord RECIST revise version 1.1 . Age &gt; = 18 year . ECOG PS 02 . Life expectancy &gt; 3 month . Signed informed consent . Uncontrolled diabetes ( glucose &gt; 200 mg/dl Any malignancy within 5 year ( except adequately treat carcinoma situ cervix basal squamous cell skin cancer surgically resect prostate cancer normal PSA ) . Pregnant lactating female . Previous medical therapy metastatic disease ( prior surgery , radiation therapy permit , well adjuvant medical therapy complete least 6 month prior study entry ) . Any poorly control illness ( include active infection , significant hepatic , renal , metabolic cardiac disease , myocardial infarction within previous 12 month ) may , accord physician 's judgement , interfere patient 's ability undergo chemotherapy and/or examination within study protocol Inability provide inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>metabolic response</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>PET</keyword>
</DOC>